Protalix BioTherapeutics (PLX) Receivables (2010 - 2026)

Protalix BioTherapeutics' Receivables history runs 17 years deep, the most recent figure standing at $2.9 million for Q1 2026.

• In Q1 2026, Receivables fell 37.13% year-over-year to $2.9 million; the TTM figure through Mar 2026 stood at $2.9 million (down 37.13% YoY), while the FY2025 annual figure was $8.8 million, up 203.88% from the prior year.
• Receivables was $2.9 million for Q1 2026 at Protalix BioTherapeutics, down from $8.8 million in the prior quarter.
• In the past five years, Receivables ranged from a high of $14.4 million in Q3 2025 to a low of $1.3 million in Q1 2023.
• Historically, Receivables has averaged $5.9 million across 5 years, with a median of $4.7 million in 2025.
• The sharpest annual moves came in 2023 and 2025: Receivables slumped 77.93% in 2023, then surged 557.18% in 2025.
• A 5-year view of Receivables shows it stood at $4.6 million in 2022, then increased by 14.96% to $5.3 million in 2023, then slumped by 44.82% to $2.9 million in 2024, then surged by 203.88% to $8.8 million in 2025, then plunged by 66.75% to $2.9 million in 2026.
• The last three Receivables figures came in at $2.9 million (Q1 2026), $8.8 million (Q4 2025), and $14.4 million (Q3 2025), per Business Quant data.